Fig. 5
SW IV-134 augments gemcitabine in a mouse xenograft model of pancreatic cancer and improves survival. a Immunocompromised female nude mice were injected in the right flank with 200 μL single cell suspension of 1 × 106 AsPC-1 cells (n = 9). Treatment started when tumors reached ~5 mm in diameter. The mice received the following treatments by i.p. injection: SW IV-134 alone (daily 750 nmoles/100 μL), vehicle (daily 100 μL as control), gemcitabine (weekly 3 mg/100 μL), and a combination of SW IV-134 (daily 750 nmoles/100 μL) and gemcitabine (weekly 3 mg/100 μL). The tumors were measured every other day using digital calipers. Of note, at the end of the treatment interval (21 days), the tumors of the mice receiving combination therapy were significantly smaller than the tumors of the other groups (p < 0.0001). b Kaplan-Meier survival curve of mice in (a). The median survival of mice treated with combination therapy was 60 days as compared to 52, 41 and 46 days for the SW IV-134, vehicle and gemcitabine groups, respectively (p = 0.02)